Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02680184 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 199
- Enrollment target
NCT02680184 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 199 participants.
The verdict
NCT02680184, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 199 participants
- Enrollment target
Study Summary
This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the study will be conducted in parallel with the Part 1 Dose Expansion Phase and will evaluate the safety and efficacy of CMP-001 when administered as a monotherapy. A Treatment Extension to assess the safety profile of CMP-001 when given in combination with pembrolizumab or as monotherapy will be available to those who are currently being treated in either Part 1 or Part 2 of this study at the time of protocol Amendment 9, v10.0.
Interventions
- DRUG Pembrolizumab
- DRUG CMP-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2016-04-12 |
| Est. Completion | 2022-12-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02680184
The ClinicalTrials.gov registry entry for NCT02680184 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02680184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02680184 about?
NCT02680184 is a clinical study titled "Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy". This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the study will be conducted i...
What is the current status of trial NCT02680184?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 199 participants. The study started on 2016-04-12. Estimated completion is 2022-12-06.
What interventions are being tested in trial NCT02680184?
The interventions under investigation include: Pembrolizumab (DRUG), CMP-001 (DRUG).
Who is sponsoring clinical trial NCT02680184?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.